Register or Sign in to Save this opportunity, or Send an Inquiry.
Inno-D07001(GemOral)
Innopharmax Inc. Taiwan flag Taiwan
Abstract ID:
INNOPHARMAX is leveraging the OralPASŪ technology to develop Gemcitabine OralPASŪ, a Phase 2 ready oral gemcitabine program with available data demonstrating \r\nStable disease in 12 patients having either advanced solid malignancies and/or malignant lympho
Send an Inquiry
RE:
Participants
You
Stable disease in 12 patients having either advanced solid malignancies and/or malignant lymphomas, nine (9) of whom were on study for ≥ three (3) months
No dose limiting toxicities (DLTs)
Low incidence of adverse events with the majority being mild-to-moderate (Grade 1 or Grade 2)

Gemcitabine OralPAS
GO PREMIUM TO GET PATENT INFORMATION
Type of Business Relationship Sought

To look for partners around the world to license out or co-develop Inno-D07001(Gemcitabine Oral)

FEATURED
Last Updated Oct 2014
Technology Type THERAPEUTIC
Phase of Development CLINICAL TRIALS
CORPORATION

Opportunity Contact